Advertisement
Screener

QUIDELORTHO CORP (QDEL) Amortization of Intangible Assets

2.8 / 5 stars · 68/120 Roast Me

QUIDELORTHO CORP Amortization of Intangible Assets

QUIDELORTHO CORP (QDEL) reported Amortization of Intangible Assets of $49.00 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-07

  • QUIDELORTHO CORP amortization of intangible assets for the quarter ending 2026-06-28 was $49.00M, a 2.30% increase year-over-year.
  • QUIDELORTHO CORP amortization of intangible assets for the quarter ending 2026-03-29 was $46.80M, a 2.50% decline year-over-year.
  • QUIDELORTHO CORP amortization of intangible assets for the quarter ending 2025-12-28 was $45.60M, a 4.80% decline year-over-year.
  • QUIDELORTHO CORP amortization of intangible assets for the quarter ending 2025-09-28 was $47.70M, a 8.09% decline year-over-year.
  • QUIDELORTHO CORP amortization of intangible assets for fiscal 2025 was $189.20M, a 6.98% decline from fiscal 2024.
  • QUIDELORTHO CORP amortization of intangible assets for fiscal 2024 was $203.40M, a 0.68% decline from fiscal 2023.
  • QUIDELORTHO CORP amortization of intangible assets for fiscal 2023 was $204.80M, a 54.57% increase from fiscal 2023.
  • QUIDELORTHO CORP amortization of intangible assets for fiscal 2023 was $132.50M, a 383.58% increase from fiscal 2022.
Period endAmortization of Intangible Assets 3 monthAmortization of Intangible Assets 6 monthAmortization of Intangible Assets 9 monthAmortization of Intangible Assets 12 month
2026-06-28$49.00M
10-Q · filed 2026-08-07
$95.80M
10-Q · filed 2026-08-07
$141.40M
derived: sum of 3 quarters · filed 2026-08-07
$189.10M
derived: sum of 4 quarters · filed 2026-08-07
2026-03-29$46.80M
10-Q · filed 2026-05-06
$92.40M
derived: sum of 2 quarters · filed 2026-05-06
$140.10M
derived: sum of 3 quarters · filed 2026-05-06
$188.00M
derived: sum of 4 quarters · filed 2026-08-07
2025-12-28$45.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$93.30M
derived: sum of 2 quarters · filed 2026-02-19
$141.20M
derived: sum of 3 quarters · filed 2026-08-07
$189.20M
10-K · filed 2026-02-19
2025-09-28$47.70M
10-Q · filed 2025-11-06
$95.60M
derived: sum of 2 quarters · filed 2026-08-07
$143.60M
10-Q · filed 2025-11-06
$191.50M
derived: sum of 4 quarters · filed 2026-08-07
2025-06-29$47.90M
10-Q · filed 2026-08-07
$95.90M
10-Q · filed 2026-08-07
$143.80M
derived: sum of 3 quarters · filed 2026-08-07
$195.70M
derived: sum of 4 quarters · filed 2026-08-07
2025-03-30$48.00M
10-Q · filed 2026-05-06
$95.90M
derived: sum of 2 quarters · filed 2026-05-06
$147.80M
derived: sum of 3 quarters · filed 2026-05-06
$199.70M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-29$47.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$99.80M
derived: sum of 2 quarters · filed 2026-02-19
$151.70M
derived: sum of 3 quarters · filed 2026-02-19
$203.40M
10-K · filed 2026-02-19
2024-09-29$51.90M
10-Q · filed 2025-11-06
$103.80M
derived: sum of 2 quarters · filed 2025-11-06
$155.50M
10-Q · filed 2025-11-06
$206.70M
derived: sum of 4 quarters · filed 2026-02-19
2024-06-30$51.90M
10-Q · filed 2025-08-06
$103.60M
10-Q · filed 2025-08-06
$154.80M
derived: sum of 3 quarters · filed 2026-02-19
$206.20M
derived: sum of 4 quarters · filed 2026-02-19
2024-03-31$51.70M
10-Q · filed 2025-05-08
$102.90M
derived: sum of 2 quarters · filed 2026-02-19
$154.30M
derived: sum of 3 quarters · filed 2026-02-19
$205.70M
derived: sum of 4 quarters · filed 2026-02-19
2023-12-31$51.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$102.60M
derived: sum of 2 quarters · filed 2026-02-19
$154.00M
derived: sum of 3 quarters · filed 2026-02-19
$204.80M
10-K · filed 2026-02-19
2023-10-01$51.40M
10-Q · filed 2024-11-08
$102.80M
derived: sum of 2 quarters · filed 2024-11-08
$153.60M
10-Q · filed 2024-11-08
$207.50M
derived: sum of 4 quarters · filed 2025-02-27
2023-07-02$51.40M
10-Q · filed 2024-08-01
$102.20M
10-Q · filed 2024-08-01
$156.10M
derived: sum of 3 quarters · filed 2025-02-27
$206.60M
derived: sum of 4 quarters · filed 2025-02-27
2023-04-02$50.80M
10-Q · filed 2024-05-09
$104.70M
derived: sum of 2 quarters · filed 2025-02-27
$155.20M
derived: sum of 3 quarters · filed 2025-02-27
$176.20M
derived: sum of 4 quarters · filed 2025-02-27
2023-01-01$53.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$104.40M
derived: sum of 2 quarters · filed 2025-02-27
$125.40M
derived: sum of 3 quarters · filed 2025-02-27
$132.50M
10-K · filed 2025-02-27
2022-10-02$50.50M
10-Q · filed 2023-11-02
$71.50M
derived: sum of 2 quarters · filed 2023-11-02
$78.60M
10-Q · filed 2023-11-02
$85.50M
derived: sum of 4 quarters · filed 2024-08-01
2022-07-03$21.00M
10-Q · filed 2023-08-09
$28.10M
10-Q · filed 2023-08-09
$35.00M
derived: sum of 3 quarters · filed 2024-08-01
$41.90M
derived: sum of 4 quarters · filed 2024-08-01
2022-04-03$7.10M
10-Q · filed 2023-05-04
$14.00M
derived: sum of 2 quarters · filed 2024-08-01
$20.90M
derived: sum of 3 quarters · filed 2024-08-01
$27.70M
derived: sum of 4 quarters · filed 2024-08-01
2022-01-02$6.90M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-08-01
$13.80M
derived: sum of 2 quarters · filed 2024-08-01
$20.60M
derived: sum of 3 quarters · filed 2024-08-01
$27.40M
10-K/A · filed 2024-08-01
2021-10-03$6.90M
10-Q · filed 2022-11-04
$13.70M
derived: sum of 2 quarters · filed 2022-11-04
$20.50M
10-Q · filed 2022-11-04
2021-07-04$6.80M
10-Q · filed 2022-08-05
$13.60M
10-Q · filed 2022-08-05
2021-01-03$27.30M
10-K · filed 2023-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92